• Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology


Case report | 21-March-2020

Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease

A case of hyperhemolytic transfusion reaction attributable to antiFy3 in a 30-year-oldAfricanAmerican woman with a history of sickle cell disease is reported. The patient was admitted for vaso-occlusive sickle cell crisis and received 4 units of packed RBCs secondary to worsening symptomatic anemia (Hb 5.0 g/dL). On admission,the patient’s antibody screen and identification showed anti-V and antiE,and her antibody history included anti-E,-C,-Jkb,-N,-V,-S,-Sla,and a cold agglutinin with

Meredith A. Reyes, Orieji C. Illoh

Immunohematology, Volume 24 , ISSUE 2, 45–51

Report | 01-December-2019

Transfusion practices for patients with sickle cell disease at major academic medical centers participating in the Atlanta Sickle Cell Consortium

The Atlanta Sickle Cell Consortium represents more than 2600 pediatric and adult patients with sickle cell disease (SCD) in the metropolitan Atlanta, Georgia, area receiving care at four major locations, each providing comprehensive care 24 hours a day, 7 days a week. Both transfusion services that support these sites use two levels of prospective phenotype matching to decrease the rates of alloimmunization. Although exact rates are unknown and are currently under investigation

Anne M. Winkler, Cassandra D. Josephson

Immunohematology, Volume 28 , ISSUE 1, 24–26

Report | 12-March-2020

Occurrence of antibodies to low-incidence antigens among a cohort of multiply transfused patients with sickle cell disease

Data from an immunohematology reference laboratory were compiled retrospectively to determine the occurrence of the formation of alloantibodies to low-incidence antigens associated with the African American population (AA-LIAs) among patients with sickle cell disease (SCD). The AA-LIAs under study were V, VS, Jsa, and Goa. The records from 137 recurrently transfused patients with SCD were selected on the basis of transfusion activity from the 2009 calendar year. We found that 13 patients (9.49

Pamela Jackson

Immunohematology, Volume 27 , ISSUE 4, 143–145

Article | 15-April-2020

In search of red blood cells for alloimmunized patients with sickle cell disease

Patients with sickle cell disease (SCD) typically require transfusions with RBC components,which exposes them to numerous,possibly foreign antigens and potentially causes them to produce an antibody or antibodies to the antigens they lack. As transfusion of these patients increases, the likelihood that they will produce an initial antibody or additional antibodies increases. Once a clinically significant antibody is produced, units of RBCs that lack the associated antigen should be transfused

Cynthia Flickinger

Immunohematology, Volume 22 , ISSUE 3, 136–142

Report | 01-December-2019

Directed blood donor program decreases donor exposure for children with sickle cell disease requiring chronic transfusion

In children with sickle cell disease (SCD), primary and secondary prevention of strokes require indefinite regular blood transfusion therapy. The risks associated with repeated transfusions include alloimmunization and increased donor exposure. The Charles Drew Program is a directed blood donor program designed to lower donor exposure, decreasing the associated complications of transfusion; however, no evidence exists demonstrating the magnitude of the benefit to the recipient. Further, the use

Dionna O. Roberts, Brittany Covert, Terianne Lindsey, Vincent Edwards, Lisa McLaughlin, John Theus, Ricardo J. Wray, Keri Jupka, David Baker, Mary Robbins, Michael R. DeBaun

Immunohematology, Volume 28 , ISSUE 1, 7–12

Article | 14-October-2020

An algorithm to locate hrB – donors for individuals with sickle cell disease

Many African Americans with sickle cell disease (SCD) develop alloantibodies to antigens in the Rh blood group system.Others have shown that from D– individuals, those lacking the high-incidence hrB antigen (> 98% prevalence) may be found among r'r African Americans. We describe an algorithm to locate units for African Americans with SCD and anti-hrB and -D. From 46,539 donations, 5136 listed African American as race. Our primary reference laboratory performed Rh phenotyping (D, C

Richard R. Gammon, Norberto D. Velasquez Jr.

Immunohematology, Volume 18 , ISSUE 3, 82–84

Article | 17-February-2021

Concordance of two polymerase chain reaction–based blood group genotyping platforms for patients with sickle cell disease

Alloimmunization is a known complication in which patients develop antibodies to non-self, red blood cell (RBC) antigens after exposure through transfusion, transplant, or pregnancy. Patients with sickle cell disease (SCD) are especially vulnerable, with up to 47 percent of transfused patients reported to be alloimmunized.1–8 A majority of these alloimmunization events occur within the Rh and Kell blood group systems. Providing antigen-matched blood for antigens in these two blood group systems

C.A. Sheppard, N.L. Bolen, G. Meny, M. Kalvelage, G. Ochoa-Garay

Immunohematology, Volume 36 , ISSUE 4, 123–128

Article | 06-December-2020

Clinical correlation of positive direct antiglobulin tests in patients with sickle cell disease

Serologic findings of immune-mediated hemolytic anemia (autoimmune hemolytic anemia and cold agglutinin disease) are not infrequent in patients with sickle cell disease and can be clinically significant. Features of sickle cell disease that may affect the emergence and intensity of immune-mediated hemolysis include the antigenic stimulation of chronic red blood cell (RBC) transfusions, increased autoantibody production, RBC membrane defects, and functional asplenism. We describe two patients

Raymond L. Comenzo, Marie E. Malachowski, Eugene M. Berkman

Immunohematology, Volume 8 , ISSUE 1, 13–16

Report | 01-December-2019

Transfusion practices for patients with sickle cell disease at the Children's Hospital of Philadelphia

Stella T. Chou, David F. Friedman

Immunohematology, Volume 28 , ISSUE 1, 27–30

Article | 15-April-2020

Transfusion practices for patients with sickle cell disease at a major academic medical center

care units),cardiothoracic surgery, pediatrics, the operating room, the emergency department, labor and delivery, dialysis, and outpatient services. UNC is recognized for its expertise in coagulation,transfusion medicine,and hematology,particularly in sickle cell disease (SCD). The sickle cell center at UNC,which began in 1980 and continues today,in conjunction with our neighboring institution,Duke University Medical Center,is designated as part of a National Institutes of Health comprehensive

Araba Afenyi-Annan, Nicholas Bandarenko

Immunohematology, Volume 22 , ISSUE 3, 103–107

Review | 20-March-2020


glycoproteins, which are members of the immunoglobulin superfamily of adhesion molecules and receptors, bind isoforms of laminin with α5 chains, components of the extracellular matrix abundant in vascular endothelia. The primary function of the Lutheran glycoproteins on RBCs could involve the transfer of maturing RBCs from the bone marrow to the peripheral circulation. They could also be involved in vascular occlusion and thrombotic events as complications of sickle cell disease and polycythemia vera

Geoff Daniels

Immunohematology, Volume 25 , ISSUE 4, 152–159

Article | 15-April-2020

The Charles Drew Program in Missouri:a description of a partnership among a blood center and several hospitals to address the care of patients with sickle cell disease

Sickle cell disease (SCD) is an inherited blood disorder which can be complicated by stroke in infancy and childhood. The primary and secondary prevention of stroke in this patient population is regular RBC transfusion therapy at least every three weeks, but there is no consensus on the ideal RBC transfusion therapy. The Charles Drew Program, a partnership among a blood center and several hospitals affiliated with academic medical centers in Missouri, provides RBCs for the care of patients with

Edahn J. Isaak, Barbara LeChien, Terianne Lindsey, Michael R. DeBaun

Immunohematology, Volume 22 , ISSUE 3, 112–116

Review | 17-March-2020

Sickle cell disease: a review

Susan D. Roseff

Immunohematology, Volume 25 , ISSUE 2, 67–74

Review | 15-April-2020

Review:clinical transfusion management in sickle cell disease

Zora R. Rogers

Immunohematology, Volume 22 , ISSUE 3, 126–131

Article | 21-April-2020

Acute hemolytic transfusion reaction secondary to anti-Fy3

A hemolytic transfusion reaction due to anti-Fy3 is reported in an African American patient with no history of sickle cell disease. This 82-year-old African American woman received two units of RBCs for anemia (Hb 7g/dL) on admission for a left hip fracture. On hospital Day 7, the patient underwent left hip endoprosthesis surgery; she received two units of RBCs on the second postoperative day due to Hb of 6.1g/dL. Her urine was dark during surgery and postoperatively. Her posttransfusion plasma

Horatiu Olteanu, David Gerber, Kara Partridge, Ravindra Sarode

Immunohematology, Volume 21 , ISSUE 2, 48–52

Book Review | 26-October-2020

BOOK REVIEW: Transfusion Support for Patients with Sickle Cell Disease

Karen E. King, Paul M. Ness

Immunohematology, Volume 15 , ISSUE 4, 170–171

Report | 01-December-2019

Transfusion protocols for patients with sickle cell disease: working toward consensus?

Geralyn M. Meny

Immunohematology, Volume 28 , ISSUE 1, 1–2

Report | 01-December-2019

Prevalence of RHD*DOL and RHCE*ce(818T)  in two populations

The alleles RHCE*ceBI (RHCE*ce 48C, 712G, 818T, 1132G) and RHCE*ceSM (RHCE*ce 48C, 712G, 818T) encode the lowprevalence Rh antigen STEM. These alleles frequently travel in cis with RHD*DOL. To estimate the frequency of these alleles, we tested a total of more than 700 samples in two populations. Blood samples were obtained from patients with sickle cell disease and from blood donors of African descent. DNA extractions and analyses were performed by standard methods. In the United States, none

Christine Halter Hipsky, Daiane Cobianchi da Costa, Ricardo Omoto, Angela Zanette, Lilian Castilho, Marion E. Reid

Immunohematology, Volume 27 , ISSUE 2, 66–67

Article | 01-April-2020

A confusion in antibody identification:anti-D production after anti-hrB

It is well known that certain combinations of alloantibodies are frequently found together. Patients with sickle cell disease (SCD) are mostly of African ancestry, and they may make anti-hrB. A transfusion of hrB– blood is often achieved by using e– (R2R2) RBCs; it is generally believed that hrB– patients readily make anti-E or a “broad-spectrum” anti-Rh34 (-HrB). We describe two multiply transfused D+ patients with SCD and a history of anti-hrB who subsequently

Christine Lomas-Francis, Rosyln Yomtovian, Claire McGrath, Phyllis S. Walker, Marion E. Reid

Immunohematology, Volume 23 , ISSUE 4, 158–160

Report | 01-December-2019

Transfusions for patients with sickle cell disease at Children's Hospital Boston

Steven R. Sloan

Immunohematology, Volume 28 , ISSUE 1, 17–19

Article | 15-April-2020

Prophylactic phenotype matching of donors for the transfusion of nonalloimmunized patients with sickle cell disease

Ira A. Shulman

Immunohematology, Volume 22 , ISSUE 3, 101–102

Article | 16-October-2019

Recovery of autologous sickle cells by hypotonic wash

It is important to isolate autologous red blood cells (RBCs) from transfused RBCs in samples from recently transfused patients to ensure that accurate serologic results are obtained. Typically, this isolation can be performed using methods that separate patient reticulocytes from transfused, older donor RBCs. Patients with sickle cell disease (SCD), however, characteristically have RBCs with altered membrane and morphological features, causing their RBCs to take on a sickle-shape appearance

Emily Wilson, Kelly Kezeor, Monica Crosby

Immunohematology, Volume 34 , ISSUE 1, 16–18

Article | 15-April-2020

Transfusion support of patients with sickle cell disease at the Children's Hospital of Philadelphia

Deborah Sesok-Pizzini, David F. Friedman, Kim Smith-Whitley, Sandra J. Nance

Immunohematology, Volume 22 , ISSUE 3, 121–125

Report | 01-December-2019

Antigen-matched red blood cell transfusions for patients with sickle cell disease at The Johns Hopkins Hospital

Matthew S. Karafin, R. Sue Shirey, Paul M. Ness, Karen E. King

Immunohematology, Volume 28 , ISSUE 1, 3–6

Report | 12-March-2020

RHCE*ceAR encodes a partial c (RH4) antigen

The Rh blood group system is highly complex both in the number of discrete antigens and in the existence of partial antigens, especially D and e.  Recently, several partial c antigens have been reported. Here we report findings on an African American man with sickle cell disease whose RBCs typed C+c+ and whose plasma contained anti-c. Hemagglutination tests, DNA extraction, PCR-RFLP, reticulocyte RNA isolation, RT-PCR cDNA analyses, cloning, and sequencing were performed by standard

Marion E. Reid, Christine Halter Hipsky, Christine Lomas-Francis, Akiko Fuchisawa

Immunohematology, Volume 26 , ISSUE 2, 57–59

Case report | 09-October-2019

Hemolytic transfusion reaction attributable to anti-Dia  

-Dia, the addition of Di(a+) cells to the reagent RBCs used for the antibody detection test along with IAT-crossmatching of donor units for all patients with sickle cell disease is recommended.

Arthur J. Joyce, Kelli M Quantock, Ray Banh, Yew-Wah Liew

Immunohematology, Volume 33 , ISSUE 1, 6–8

Report | 01-December-2019

The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells

Elliott Vichinsky

Immunohematology, Volume 28 , ISSUE 1, 20–23

Article | 15-April-2020

Partners for Life: the transfusion program for patients with sickle cell disease offered at the American Red Cross Blood Services, Southern Region, Atlanta, Georgia

Krista L. Hillyer, Virginia W. Hare, Cassandra D. Josephson, Shealynn B. Harris, Christopher D. Hillyer

Immunohematology, Volume 22 , ISSUE 3, 108–111

Report | 24-March-2020

Cryopreserving and deglycerolizing sickle cell trait red blood cell components using an automated cell-processing system

RBC components with rare phenotypes are sometimes required for patients with sickle cell disease, and these rare components can often be found among donors with sickle cell trait.  Cryopreserving RBC components from sickle cell trait donors requires a modified deglycerolization method to preserve the integrity of the RBCs.  This study evaluated the feasibility of using an automated cell-processing system to cryopreserve and deglycerolize sickle cell trait donor RBC components. 

Ricci Jo Ackley, A. Hallie Lee-Stroka, Barbara J. Bryant, David F. Stroncek, Karen M. Byrne

Immunohematology, Volume 24 , ISSUE 3, 107–111

Original Paper | 09-October-2019

Modeling alloantibody formation to highincidence red blood cell antigens in immune responders using genotypic data  

HIA (12.5% of all, 13.8% of those with a documented exposure). Two of these four patients (50%) had made an alloantibody to another antigen. The odds of forming an antibody to an HIA were not related to the total number of transfusions (p = 0.47), the total number of alloantibodies (p = 0.61), or diagnosis of sickle cell disease (p = 0.77) in simple logistic regression. Adjustment for the other two variables in a multiple logistic regression was also not significant for each variable (p = 0.6, p

Patricia A.R. Brunker, Keerthana Ravindran, R. Sue Shirey

Immunohematology, Volume 33 , ISSUE 1, 9–14

Report | 09-October-2019

Red blood cell phenotype prevalence in blood donors who self-identify as Hispanic

Molecular genotyping platforms provide a quick, high-throughput method for identifying red blood cell units for patients on extended phenotype-matching protocols, such as those with sickle cell disease or thalassemia. Most of the antigen prevalence data reported are for non-Hispanic populations. Therefore, this study sought to determine the phenotype prevalence in a single blood center’s Hispanic population and to compare those results with previously reported rates in non-Hispanic donor

Chelsea A. Sheppard, Nicole L. Bolen, Beth Eades, Gorka Ochoa-Garay, Mark H. Yazer

Immunohematology, Volume 33 , ISSUE 3, 119–124

Article | 15-April-2020

Molecular characterization of GYPB and RH in donors in the American Rare Donor Program

Transfusion of patients with sickle cell disease (SCD) has been a challenge in clinical transfusion medicine, especially when the required donor RBCs must be U– and negative for high-prevalence Rh phenotypes (hrB,hrS). It is now possible to genotype donors to identify or confirm Uvar and U– phenotypes,as well as Rh hrB– and hrS– phenotypes,and to characterize the different RH backgrounds found in these donors. In a preliminary study of donors registered in the American

Sunitha Vege, Connie M. Westhoff

Immunohematology, Volume 22 , ISSUE 3, 143–147

Case report | 09-October-2019

A suspected delayed hemolytic transfusion reaction mediated by anti-Joa

A 32-year-old African-American woman with a history of sickle cell disease presented for surgical evaluation of left total hip arthroplasty due to avascular necrosis of the femoral head. In anticipation of a complex orthopedic procedure, pre-surgical blood work was ordered. The patient’s Fenwal blood sample typed as group O, D+. Although the patient had a history of anti-Fya, the antibody identification was inconclusive, so the workup was sent to a reference laboratory. The patient was

Ryan P. Jajosky, Wendy C. Lumm, Scott C. Wise, Roni J. Bollag, James F. Shikle

Immunohematology, Volume 33 , ISSUE 2, 73–75

No Record Found..
Page Actions